Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in site-specific and novel-format antibody drug conjugates (ADCs), has announced its participation in the TD Cowen 45th Annual Health Care Conference. The conference is scheduled for March 3-5, 2025, in Boston, MA.
The company's management will deliver a presentation, which will be made available through the News & Events page in the Investor Relations section of Sutro's website (www.sutrobio.com). Interested parties can access an archived replay of the presentation for a minimum of 30 days following the event.
Sutro Biopharma (NASDAQ: STRO), un'azienda oncologica in fase clinica specializzata in coniugati di farmaci ad anticorpi (ADC) specifici per il sito e in formati innovativi, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La conferenza si terrà dal 3 al 5 marzo 2025 a Boston, MA.
La direzione dell'azienda presenterà un intervento, che sarà reso disponibile attraverso la pagina News & Events nella sezione Relazioni con gli Investitori del sito web di Sutro (www.sutrobio.com). Le parti interessate potranno accedere a una registrazione archiviata della presentazione per un minimo di 30 giorni dopo l'evento.
Sutro Biopharma (NASDAQ: STRO), una empresa oncológica en etapa clínica especializada en conjugados de fármacos anticuerpos (ADC) específicos del sitio y en formatos novedosos, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La conferencia está programada del 3 al 5 de marzo de 2025 en Boston, MA.
La dirección de la empresa realizará una presentación, que estará disponible a través de la página de Noticias y Eventos en la sección de Relaciones con Inversores de la página web de Sutro (www.sutrobio.com). Las partes interesadas podrán acceder a una repetición archivada de la presentación durante un mínimo de 30 días después del evento.
수트로 바이오파마 (NASDAQ: STRO)는 사이트 특정 및 혁신적인 형식의 항체 약물 접합체(ADC)를 전문으로 하는 임상 단계의 종양학 회사로, TD 코웬 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 이 회의는 2025년 3월 3일부터 5일까지 매사추세츠주 보스턴에서 열릴 예정입니다.
회사의 경영진은 발표를 진행할 예정이며, 이 발표는 수트로 웹사이트(www.sutrobio.com)의 투자자 관계 섹션의 뉴스 및 이벤트 페이지를 통해 제공될 것입니다. 관심 있는 분들은 행사 후 최소 30일 동안 발표의 아카이브 재생을 이용할 수 있습니다.
Sutro Biopharma (NASDAQ: STRO), une entreprise de biopharmacie en phase clinique spécialisée dans les conjugués de médicaments à base d'anticorps (ADC) spécifiques au site et en formats novateurs, a annoncé sa participation à la 45ème Conférence Annuelle de Santé de TD Cowen. La conférence est prévue du 3 au 5 mars 2025 à Boston, MA.
La direction de l'entreprise fera une présentation, qui sera rendue disponible via la page Actualités & Événements dans la section Relations Investisseurs du site de Sutro (www.sutrobio.com). Les parties intéressées pourront accéder à un enregistrement archivé de la présentation pendant un minimum de 30 jours suivant l'événement.
Sutro Biopharma (NASDAQ: STRO), ein Unternehmen in der klinischen Phase, das sich auf standortspezifische und neuartige Antikörper-Wirkstoff-Konjugate (ADCs) spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Konferenz findet vom 3. bis 5. März 2025 in Boston, MA statt.
Das Management des Unternehmens wird eine Präsentation halten, die über die Seite Nachrichten & Veranstaltungen im Bereich Investor Relations der Website von Sutro (www.sutrobio.com) verfügbar gemacht wird. Interessierte Parteien können eine archivierte Wiederholung der Präsentation für mindestens 30 Tage nach der Veranstaltung abrufen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA.
The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
When is Sutro Biopharma (STRO) presenting at the TD Cowen Healthcare Conference 2025?
How long will Sutro Biopharma's (STRO) TD Cowen conference presentation be available for replay?
Where can investors access Sutro Biopharma's (STRO) TD Cowen conference presentation?
What is Sutro Biopharma's (STRO) main focus in oncology development?
